Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | PNLIP | P16233 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540179 | 0.88 | CTNNB1 (0.62) | MEN1KMT2ASLC6A3HTTMAPT | |
| SCHEMBL4382990 | 0.87 | CYP1A2 (0.65) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8782253 | 0.87 | SLC6A3 (0.61) | MEN1KMT2ASLC6A3MAPTRAB9A | |
| SCHEMBL27850308 | 0.87 | SLC6A3 (0.64) | MEN1KMT2ACYP1A2CYP2C19SLC6A3 | |
| Hydrochloric Acid SCHEMBL6690115 | 0.86 | CTNNB1 (0.61) | MEN1KMT2ASLC6A3HTTMAPT | |
| SCHEMBL28044475 | 0.86 | PNLIP (0.46) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15897488 | 0.85 | SLC6A3 (0.60) | MEN1KMT2ASLC6A3HTTMAPT | |
| SCHEMBL14334681 | 0.85 | MEN1 (0.55) | MEN1KMT2ASLC6A3MAPTNPSR1 | |
| SCHEMBL11421571 | 0.85 | SLC6A3 (0.55) | MEN1KMT2ASLC6A3MAPTNPSR1 | |
| SCHEMBL4384831 | 0.84 | CYP1A2 (0.62) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829854-B1 | PROCESS FOR PRODUCING AROMATIC CARBONATE | ASAHI KASEI CHEMICALS CORP (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7629485-B2 | Process for producing aromatic carbonate | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20080177099-A1 | Process for Producing Aromatic Carbonate | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1829854-A1 | PROCESS FOR PRODUCING AROMATIC CARBONATE | Asahi Kasei Chemicals Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1016648-B1 | PROCESS FOR THE PREPARATION OF AROMATIC CARBONATES | ASAHI CHEMICAL IND (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6262210-B1 | TRANSESTERIFYING DIALKYL CARBONATE, ALKYL ARYL CARBONATE OR MIXTURE WITH AROMATIC MONOHYDROXY COMPOUND IN PRESENCE OF METAL CONTAINING CATALYST TO OBTAIN HIGH BOILING POINT REACTION MIXTURE CONTAINING AROMATIC CARBONATE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-07-17 | — | — | US | disclosed |
| EP-1016648-A1 | PROCESS FOR THE PREPARATION OF AROMATIC CARBONATES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-07-05 | — | — | EP | disclosed |
| EP-0733366-B1 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | DU PONT (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0324377-B1 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | DU PONT (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0733366-A2 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0253310-B1 | Angiotensin II receptor blocking imidazoles | DU PONT (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4113782-A | CATALYTIC OXIDATION | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177099-A1 | Process for Producing Aromatic Carbonate | DCLK1, ALK, DCLK3 | MEN1 2201/4885KMT2A 2526/4885CYP1A2 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.